Palliative Radiotherapy for Dysphagia in Esophageal Cancer: Short-Term Benefits and Late Toxicity Risks.

Area of Science:

• Oncology
• Radiation Oncology
• Palliative Care

Background:

• Esophageal cancer often presents at advanced stages, with dysphagia significantly impacting quality of life (QOL).
• Palliative radiotherapy is a common treatment for dysphagia, but its efficacy and safety profile require further clarification.

Purpose of the Study:

• To evaluate the effectiveness of palliative radiotherapy in improving dysphagia in esophageal cancer patients.
• To assess treatment-related toxicities and overall survival (OS) associated with palliative radiotherapy.

Main Methods:

• Retrospective analysis of 58 esophageal cancer patients with dysphagia treated with palliative radiotherapy (30-40 Gy).
• Assessment of dysphagia scores pre- and post-radiotherapy, concurrent chemotherapy use, OS, and toxicities.
• Evaluation of outcomes based on disease stage (T3 vs. T4b).

Main Results:

• 78% of patients showed dysphagia improvement within a median of 35 days.
• Dysphagia recurrence occurred in 38% of improved patients, with a median survival of 1.2 months post-recurrence.
• Concurrent chemotherapy suggested higher dysphagia improvement rates. T4b disease showed a high incidence of late esophageal/bronchial fistulas (36%) compared to T3 (6.7%).

Conclusions:

• Palliative radiotherapy effectively improves short-term dysphagia in most esophageal cancer patients.
• T4b disease patients face increased risks of severe late adverse events, mandating careful patient selection.
• Shared decision-making is essential, discussing potential benefits, recurrence risks, and late toxicities with patients.